Patient characteristics according to TRK expression
| Characteristic . | Total . | TRK−, % of total=column 2 . | TRK+, % of total=column 2 . | P, between TRK+ and TRK− . |
|---|---|---|---|---|
| Patients, no. (%) | 94 | 42 (45) | 52 (55) | |
| Age, y | ||||
| Mean | 54.3 | 52.9 | 55.5 | .41 |
| Range | 16-79 | 20-77 | 16-79 | |
| Sex, no. | .17 | |||
| Male | 52 | 27 | 25 | |
| Female | 42 | 15 | 27 | |
| Leukemia, no. (%) | .358 | |||
| AML | 82 | 39 (48) | 43 (52) | |
| ALL | 11 | 3 (27) | 8 (73) | |
| AUL | 1 | 0 | 1 | |
| Diagnosis (AML), no. (%) | .057 | |||
| De novo | 58 | 32 (55) | 26 (45) | |
| Post-MDS/secondary | 24 | 7 (29) | 17 (71) | |
| FAB subtype AML | .003 | |||
| M0 | 3 | 3 | 0 | |
| M1 | 25 | 16 | 9 | |
| M2 | 17 | 10 | 7 | |
| M3 | 1 | 1 | 0 | |
| M4 | 21 | 9 | 12 | |
| M5 | 13 | 0 | 13 | |
| M6 | 1 | 0 | 1 | |
| M7 | 1 | 0 | 1 | |
| % Blasts | ||||
| Bone marrow | 73 | 76 | 70 | .280 |
| Peripheral blood | 44 | 49 | 39 | .173 |
| WBC counts, ×109/L | ||||
| Mean | 24.4 | 61.0 | .113 (cutoff: 20.000)40 | |
| Range | 0.8-159.0 | 0.6-454.0 | ||
| ECOG status | .764 | |||
| 0 | 22 | 10 | 12 | |
| 1 | 52 | 25 | 27 | |
| 2 | 13 | 7 | 6 | |
| 3 | 1 | 0 | 1 | |
| Cytogenetics, no. (%) | .481 | |||
| Normal karyotype | 39 | 17 (44) | 22 (56) | |
| t(8;21) (q22;q22) | 1 | 1 | 0 | |
| inv(16) (p13q12) | 1 | 1 | 0 | |
| t(15:17)(q22;q11-21) | 1 | 1 | 0 | |
| t(11q23) | 2 | 1 | 1 | |
| Complex karyotype* | 21 | 11 | 10 | |
| Other aberrations | 24 | 8 | 16 | |
| FLT3-ITD−, no. (%) | 50 | 26 (52) | 24 (48) | .363 |
| FLT3-ITD+, no. (%) | 17 | 6 (35) | 11 (65) | |
| Missing | 17 (18) |
| Characteristic . | Total . | TRK−, % of total=column 2 . | TRK+, % of total=column 2 . | P, between TRK+ and TRK− . |
|---|---|---|---|---|
| Patients, no. (%) | 94 | 42 (45) | 52 (55) | |
| Age, y | ||||
| Mean | 54.3 | 52.9 | 55.5 | .41 |
| Range | 16-79 | 20-77 | 16-79 | |
| Sex, no. | .17 | |||
| Male | 52 | 27 | 25 | |
| Female | 42 | 15 | 27 | |
| Leukemia, no. (%) | .358 | |||
| AML | 82 | 39 (48) | 43 (52) | |
| ALL | 11 | 3 (27) | 8 (73) | |
| AUL | 1 | 0 | 1 | |
| Diagnosis (AML), no. (%) | .057 | |||
| De novo | 58 | 32 (55) | 26 (45) | |
| Post-MDS/secondary | 24 | 7 (29) | 17 (71) | |
| FAB subtype AML | .003 | |||
| M0 | 3 | 3 | 0 | |
| M1 | 25 | 16 | 9 | |
| M2 | 17 | 10 | 7 | |
| M3 | 1 | 1 | 0 | |
| M4 | 21 | 9 | 12 | |
| M5 | 13 | 0 | 13 | |
| M6 | 1 | 0 | 1 | |
| M7 | 1 | 0 | 1 | |
| % Blasts | ||||
| Bone marrow | 73 | 76 | 70 | .280 |
| Peripheral blood | 44 | 49 | 39 | .173 |
| WBC counts, ×109/L | ||||
| Mean | 24.4 | 61.0 | .113 (cutoff: 20.000)40 | |
| Range | 0.8-159.0 | 0.6-454.0 | ||
| ECOG status | .764 | |||
| 0 | 22 | 10 | 12 | |
| 1 | 52 | 25 | 27 | |
| 2 | 13 | 7 | 6 | |
| 3 | 1 | 0 | 1 | |
| Cytogenetics, no. (%) | .481 | |||
| Normal karyotype | 39 | 17 (44) | 22 (56) | |
| t(8;21) (q22;q22) | 1 | 1 | 0 | |
| inv(16) (p13q12) | 1 | 1 | 0 | |
| t(15:17)(q22;q11-21) | 1 | 1 | 0 | |
| t(11q23) | 2 | 1 | 1 | |
| Complex karyotype* | 21 | 11 | 10 | |
| Other aberrations | 24 | 8 | 16 | |
| FLT3-ITD−, no. (%) | 50 | 26 (52) | 24 (48) | .363 |
| FLT3-ITD+, no. (%) | 17 | 6 (35) | 11 (65) | |
| Missing | 17 (18) |
Complex karyotype was defined as 3 or more cytogenetic abnormalities in the absence of t(8;21), inv(16), t(15;17), or t(11q23).41